AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

181.990

+3.3101.85%

Volume:1.41M

Turnover:253.99M

Market Cap:87.16B

PE:-23.71

High:181.990

Open:178.500

Low:178.010

Close:178.680

52wk High:216.734

52wk Low:88.830

Shares:478.91M

Float Shares:478.91M

Volume Ratio:1.47

T/O Rate:0.29%

Dividend:4.19

Dividend Rate:2.30%

EPS(TTM):-7.675

EPS(LYR):-7.673

ROE:-15.83%

ROA:7.26%

PB:4.11

PE(LYR):-23.72

Loading ...

Overview Company News Filings

CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says

MT Newswires Live

Prices Us$1,000 Mln 10-Year Notes at 6.201% Fixed Rate Coupon

THOMSON REUTERS

Settlement of Notes Expected on October 14, 2026

THOMSON REUTERS

CSL Limited-CSL Prices Us$1.5 Billion in Corporate Bonds

THOMSON REUTERS

Prices Us$500 Mln 7-Year Notes at 5.948% Fixed Rate Coupon

THOMSON REUTERS

Notes to be Issued by Cslb. and Guaranteed by CSL

THOMSON REUTERS

Proceeds to be Used to Refinance Debt and for General Corporate Purposes

THOMSON REUTERS

Learn Why The Bull Case For CSL (ASX:CSL) Could Change Following Rare Disease Drug Partnership

Simply Wall St.

CSL's Licensing Deal for Lixudebart Signals Current R&D Philosophy

Jefferies Raise Price Target on Australia's CSL After Alentis Licensing Deal

Asia Morning Call-Global Markets

3 US Dividend Stocks For Investors Seeking Reliable Income In Higher Rate Markets

Simply Wall St.

Swiss Stocks - Factors to Watch on October 5

Australian Shares Rise as Commodity-Linked Stocks Advance

ASX Preview: Australian Shares to Rise as Oil Climbs on Saudi Attacks; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug

MT Newswires Live

CSL Enters Global Lixudebart Partnership with Alentis, Pays Us$355 Million Upfront

CSL and Alentis Announce Global Partnership to Develop and Commercialise Lixudebart for Rare Kidney and Liver Diseases

THOMSON REUTERS

Australia's CSL Strikes Kidney, Liver Disease Drug Deal Worth up to $1.6 Billion

To Pay Alentis $355 Mln Upfront and up to $1.2 Bln in Milestones

THOMSON REUTERS

To Fully Fund Phase 2 and Phase 3 Trials for Lixudebart

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sgp.itiger.com/stock/CSL.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":181.99,"timestamp":1791349920000,"preClose":178.68,"halted":0,"volume":1408941,"delay":0,"changeRate":0.018524736959928376,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.674505861108999,"marketStatus":"Closed","change":3.31,"latestTime":"10-07 16:12:00 AEDT","open":178.5,"high":181.99,"low":178.01,"amount":253991643,"amplitude":0.022274,"askPrice":182,"askSize":4172,"bidPrice":181.2,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-7.674505861108999,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791414000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":178.68,"dividendRate":0.022371,"openAndCloseTimeList":[[1791327600000,1791349200000]],"volumeRatio":1.469121,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":178.68,"auctionPrice":181.95,"auctionVolume":339014,"auctionTime":1791349803595,"referencePrice":181.99,"referenceTime":1791360000925,"auction":3,"marketStatus":"盘后竞价","timestamp":1791349803595}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.673298,"volumeRatio":1.469121,"shares":478911979,"dividePrice":4.188043,"high":181.99,"amplitude":0.022274,"preClose":178.68,"low":178.01,"week52Low":88.83,"pbRate":"4.11","psRate":"3.85","week52High":216.734,"institutionHeld":0,"latestPrice":181.99,"committee":-0.985721,"eps":-7.674505861108999,"divideRate":0.023012,"volume":1408941,"delay":0,"ttmEps":-7.674505861108999,"open":178.5,"prevYearClose":168.21,"prevWeekClose":175.35,"prevMonthClose":184.22,"prevQuarterClose":184.22,"fiveDayClose":184.22,"twentyDayClose":171.21,"sixtyDayClose":120.175,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.01866467227077263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673671490","title":"CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2673671490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673671490?lang=en_us&edition=fundamental","pubTime":"2026-10-07 12:10","pubTimestamp":1791346251,"startTime":"0","endTime":"0","summary":"CSL's  deal with Alentis Therapeutics for Lixudebart, a therapy candidate for anti-neutrophil cytoplasmic antibodies-associated vasculitis and rapidly progressive glomerulonephritis, is low-risk but low-reward, RBC Capital Markets said in a Thursday note.It noted that the clinical and commercial aspects of Lixudebart are unknown and the timeframe to first potential commercial revenues is fairly long. The deal's PoS adjusted net present value is AU$415 million.RBC reduced CSL's earnings per share forecasts by 0.1% to 0.4% for fiscal 2027 to fiscal 2029.The brokerage assigned an outperform rating to CSL and raised the price target to AU$215 from AU$213.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LU0029864427.USD","LU0310800379.SGD","LU0708994859.HKD","LU1267930573.SGD","GSIB","BK7501","BK4207","CSL.AU","LU0128525929.USD","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673662090","title":"Prices Us$1,000 Mln 10-Year Notes at 6.201% Fixed Rate Coupon","url":"https://stock-news.laohu8.com/highlight/detail?id=2673662090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673662090?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CSL.AU","BK7067","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673306620","title":"Settlement of Notes Expected on October 14, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673306620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673306620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","BK7511","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673208066","title":"CSL Limited-CSL Prices Us$1.5 Billion in Corporate Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2673208066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673208066?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7511","BK7067","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066270","title":"Prices Us$500 Mln 7-Year Notes at 5.948% Fixed Rate Coupon","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066270?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7511","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066206","title":"Notes to be Issued by Cslb. and Guaranteed by CSL","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066206?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7067","BK7501","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066205","title":"Proceeds to be Used to Refinance Debt and for General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066205?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CSL.AU","BK7067","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673055216","title":"Learn Why The Bull Case For CSL (ASX:CSL) Could Change Following Rare Disease Drug Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055216","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055216?lang=en_us&edition=fundamental","pubTime":"2026-10-06 17:19","pubTimestamp":1791278359,"startTime":"0","endTime":"0","summary":"CSL and Alentis Therapeutics recently agreed an exclusive global collaboration to co-develop and co-promote lixudebart for rare kidney and liver diseases, with CSL funding Phase 2 and Phase 3 programs and Alentis eligible for a US$355 million upfront payment plus up to US$1.2b in milestones and shared profits.\nThe structure of the lixudebart deal, with CSL taking on full development funding and a 55% share of global profits, signals a clear commitment to expand its nephrology and rare...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/learn-why-the-bull-case-for-csl-asxcsl-could-change-followin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/learn-why-the-bull-case-for-csl-asxcsl-could-change-followin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7067","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673824820","title":"CSL's Licensing Deal for Lixudebart Signals Current R&D Philosophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2673824820","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673824820?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:50","pubTimestamp":1791237000,"startTime":"0","endTime":"0","summary":"2149 GMT - CSL's deal with Alentis Therapeutics to jointly develop and promote a rare kidney and liver disease treatment is emblematic of its current research and development philosophy, suggests Jeff","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7067","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673708453","title":"Jefferies Raise Price Target on Australia's CSL After Alentis Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2673708453","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673708453?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:33","pubTimestamp":1791232419,"startTime":"0","endTime":"0","summary":"BUZZ-Jefferies raise price target on Australia's CSL after Alentis licensing deal** Jefferies raise CSL'sCSL.AXprice target to A$161.50 from A$146.50 after companylicensedlixudebart, a Phase 2 anti-fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R1C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7067","CSL.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673089924","title":"Asia Morning Call-Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2673089924","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673089924?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:30","pubTimestamp":1791225047,"startTime":"0","endTime":"0","summary":"Asia Morning Call-Global MarketsOct 6 (Reuters)-Stock MarketsNet ChngStock MarketsNet ChngS&P/ASX 200**8,686.4073.50NZX 50**13,699.0218.53DJIA51,310.49139.86NIKKEI**69,946.41,637.40Nasdaq27,437.26-25.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R15R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673089740","title":"3 US Dividend Stocks For Investors Seeking Reliable Income In Higher Rate Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2673089740","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673089740?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:22","pubTimestamp":1791224560,"startTime":"0","endTime":"0","summary":"Higher rates, sticky inflation risk and heavy AI spending have pulled investors in different directions, yet one theme keeps resurfacing. Reliable dividends from financially solid companies suddenly look less boring and more like ballast. When cash yields compete with equities, income streams backed by strong balance sheets can matter a lot more. This article walks through three high-quality dividend stocks exposed to these cross currents and explains why each one merits a closer look.\nThe...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/269231-card/1789128729799","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/269231-card/1789128729799"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-emr/emerson-electric/news/3-us-dividend-stocks-for-investors-seeking-reliable-income-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-emr/emerson-electric/news/3-us-dividend-stocks-for-investors-seeking-reliable-income-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0054578231.USD","SG9999003800.SGD","CSL","BK7067","BK4086","IE00BVYPNV92.GBP","BK4543","SG9999011175.SGD","BK7508","LU0511384066.AUD","CSL.AU","ISBC","LU0069063385.USD","LU0472753341.HKD","LU0557290698.USD","LU0728928796.USD","IE00BDGV0183.EUR","BK4585","BK4096","LU0289739343.SGD","BK4533","SGXZ23171101.USD","SG9999004303.SGD","IE00B3PB1722.GBP","BK4149","OSK","IE00B42XCP33.USD","BK4211","EMR.AU","BK7511","LU0057025933.USD","LU2355687059.USD","IE00BVYPNW00.USD","LU2211817866.USD","LU0289961442.SGD","BK4588","BK7104","IE00BGHQF631.EUR","LU1169590202.USD","BK7501","EMR","LU1169589451.USD","BK4597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673777897","title":"Swiss Stocks - Factors to Watch on October 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2673777897","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673777897?lang=en_us&edition=fundamental","pubTime":"2026-10-05 13:08","pubTimestamp":1791176909,"startTime":"0","endTime":"0","summary":"Swiss stocks - Factors to watch on October 5ZURICH/GDANSK, Oct 5 (Reuters)-Here are some of the main factors that may affect Swiss stocks on Monday:NESTLENEST.NSA sample of Nestle's low-fat dairy whit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL8N45O0M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7508","CSL.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673779443","title":"Australian Shares Rise as Commodity-Linked Stocks Advance","url":"https://stock-news.laohu8.com/highlight/detail?id=2673779443","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673779443?lang=en_us&edition=fundamental","pubTime":"2026-10-05 08:45","pubTimestamp":1791161131,"startTime":"0","endTime":"0","summary":"Australian shares rise as commodity-linked stocks advanceOct 5 (Reuters)-Australian shares rose on Monday, supported by gains in mining, financial and energy stocks, while investors continued to asses","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R003:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0955623706.USD","STO.AU","BK7507","CSL.AU","LU0345777659.USD","IE00BQJZX424.USD","RIO.AU","BK7095","XRO.AU","LU0971552673.USD","LU0654597011.USD","WDS.AU","BHP.AU","BK7067","LU0345781412.USD","LU1046248800.SGD","BK7508","RIO.UK","LU1023059493.AUD","LU0572939691.SGD","LU0266512127.USD","LU0630314457.HKD","LU1078025761.USD","LU2463526074.USD","LU0788109121.HKD","SG9999001143.SGD","WBC.AU","LU0505663152.USD","LU0171293334.USD","LU0330918003.SGD","BK7501","IE00BWDBJ516.SGD","LU1481600234.SGD","BK7142","IE0034235071.USD","LU0955669360.SGD","BK7503","LU1064927863.SGD","BK5111","LU1309081286.SGD","LU0971552830.HKD","BK7511","LU0161305163.EUR","LU0266512473.USD","LU0898667661.SGD","LU0612318385.USD","LU1430597077.USD","LU0264606111.USD","BK7135","LU1302929846.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776492","title":"ASX Preview: Australian Shares to Rise as Oil Climbs on Saudi Attacks; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776492","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776492?lang=en_us&edition=fundamental","pubTime":"2026-10-05 07:07","pubTimestamp":1791155252,"startTime":"0","endTime":"0","summary":"Australian shares are poised to rise on Monday after oil prices climbed as attacks claimed by Yemen's Iran-backed Houthis on Saudi Aramco sites raised concerns about potential disruptions to crude production.Oil prices were also supported after the Organization of the Petroleum Exporting Countries decided to keep its November output targets unchanged, limiting expectations for additional supply and helping keep Brent crude above $100 a barrel amid the Iran war.On Oct. 2, the S&P 500, the Nasdaq Composite, and the Dow Jones Industrial Average rose 0.7%, 1.2%, and 0.5%, respectively.In the macroeconomy, Australia's private-sector growth slowed in September as weaker new business weighed on services activity, prompting a resumption of job cuts while inflationary pressures intensified, according to a monthly survey by S&P Global released Monday.In corporate news, CSL  entered a partnership with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first-in-class therapy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VAP.AU","XAO.AU","VAS.AU","BK7511","XKO.AU","BK4139","EIGA.AU","CMM.AU","BK7067","XJO.AU","LENZ","BK7501","QFN.AU","BEAR.AU","CSL.AU","BK4539","STW.AU","GIVE.AU","BK7104","QRE.AU","SLF.AU","IMLC.AU","DACE.AU","BBOZ.AU","IISV.AU","GEAR.AU","IOZ.AU","ZYAU.AU","BK4007","BK7508","OZF.AU","IIGF.AU","OZR.AU","E200.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673768577","title":"CSL Enters Global Lixudebart Partnership with Alentis, Pays Us$355 Million Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2673768577","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673768577?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:42","pubTimestamp":1791150175,"startTime":"0","endTime":"0","summary":"CSL enters global lixudebart partnership with Alentis, pays US$355 million upfrontCSL entered an exclusive global collaboration with Alentis Therapeutics to co-develop, co-promote lixudebart for rare ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nNDL9fTHVp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CSL.AU","BK7511","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776854","title":"CSL and Alentis Announce Global Partnership to Develop and Commercialise Lixudebart for Rare Kidney and Liver Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776854","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776854?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:42","pubTimestamp":1791150151,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUABRZMKD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","BK7067","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673750477","title":"Australia's CSL Strikes Kidney, Liver Disease Drug Deal Worth up to $1.6 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2673750477","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673750477?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:37","pubTimestamp":1791149849,"startTime":"0","endTime":"0","summary":"Australia's CSL strikes kidney, liver disease drug deal worth up to $1.6 billionOct 5 -Australia's CSLCSL.AXsaid on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion before development funding.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nL1N45Q05Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","CSL.AU","BK7508","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775745","title":"To Pay Alentis $355 Mln Upfront and up to $1.2 Bln in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775745?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7511","BK7067","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775723","title":"To Fully Fund Phase 2 and Phase 3 Trials for Lixudebart","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775723","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775723?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}